Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

Autor: MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O

Publikováno v: Diabetes, Metabolic Syndrome and Obesity, Vol 2015, Iss default, Pp 241-253 (2015)

Leigh MacConell,1 Kate Gurney,2 Jaret Malloy,1 Ming Zhou,3 Orville Kolterman4 1Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA; 2Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA; 3Biostatistics, Bristol-Myers Squibb, Princeton

Externí odkaz: https://doaj.org/article/eef3036ef72f411aa398b6c9392b9ef7

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

Autor: Gurney K, Brown C, MacConell L, Han J

Publikováno v: Diabetes, Metabolic Syndrome and Obesity, Vol 2012, Iss default, Pp 29-41 (2012)

Leigh MacConell, Carl Brown, Kate Gurney, Jenny HanAmylin Pharmaceuticals, Inc. San Diego, CA, USABackground: Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist approved for the treatment of type 2 diabetes. The objectiv

Externí odkaz: https://doaj.org/article/fd89b9880170477489a05b4961494654

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Autor: Nevens, F, Andreone, P, Mazzella, G, Strasser, S, Bowlus, C, Drenth, J, Pockros, P, Regula, J, Beuers, U, Trauner, M, Jones, D, Floreani, A, Hohenester, S, Luketic, V, Shiffman, M, van Erpecum, K, Vargas, V, Vincent, C, Hirschfield, G, Shah, H, Hansen, B, Lindor, K, Marschall, H, Kowdley, K, Hooshmand Rad, R, Marmon, T, Sheeron, S, Pencek, R, Macconell, L, Pruzanski, M, Shapiro, D. Collaborator: Carbone, INVERNIZZI, PIETRO

Publikováno v: New England Journal of Medicine, 375(7), 631-643. Massachussetts Medical Society
New England journal of medicine, 375(7), 631-643. Massachussetts Medical Society
New England Journal of Medicine, 375(7), 631. Massachussetts Medical Society
The New England Journal of Medicine, 375, 631-43
The New England Journal of Medicine, 375, 7, pp. 631-43

none 32 BACKGROUND Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or dea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c1282490c2e4da3e25822cd675fd58e
https://doi.org/10.1056/nejmoa1509840

Long-term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression

Autor: Bowlus, C.L., Trauner, M., Liberman, A., Malecha, E., MacConell, L., Kremer, A.E., Nevens, F., Floreani, A.

Publikováno v: In Digestive and Liver Disease March 2021 53 Supplement 1:S18-S18

OC.05.5 OBETICHOLIC ACID TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: A SECONDARY ANALYSIS OF THE REGENERATE STUDY ACROSS FIBROSIS STAGES

Autor: Sanyal, A.J., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q.M., Goodman, Z., Bedossa, P., Khalili, M., Boursier, J., Stinton, L., Marchesini, G., Allison, M., George, J., Arkkila, P., Bugianesi, E., Zaru, L., Macconell, L., Shringarpure, R., Younossi, Z.

Publikováno v: In Digestive and Liver Disease 1 October 2020 52 Supplement 2:S19-S20